Provided by Tiger Trade Technology Pte. Ltd.

Zentalis Pharmaceuticals, LLC

3.76
-0.0650-1.70%
Post-market: 3.830.0700+1.86%19:30 EDT
Volume:988.68K
Turnover:3.79M
Market Cap:355.97M
PE:-1.92
High:3.96
Open:3.84
Low:3.75
Close:3.83
52wk High:6.95
52wk Low:1.21
Shares:94.67M
Float Shares:76.90M
Volume Ratio:0.72
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9591
EPS(LYR):-1.9100
ROE:-66.75%
ROA:-33.15%
PB:2.48
PE(LYR):-1.97

Loading ...

Zentalis Pharmaceuticals Inc Expected to Post a Loss of 49 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Zentalis Pharmaceuticals Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Jul 24

Zentalis initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jul 23

Zentalis grants 191,000 inducement stock options priced at $3.98 per share

Reuters
·
Jun 02

Press Release: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Jun 02

Zentalis Pharma director Shannon Campbell files initial beneficial ownership statement

Reuters
·
May 28

Zentalis adds Shannon Campbell to board of directors

Reuters
·
May 28

Zentalis Strengthens Commercial Leadership With Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as Svp of Commercial Strategy

THOMSON REUTERS
·
May 28

Zentalis Pharmaceuticals (ZNTL) Receives a Buy from H.C. Wainwright

TIPRANKS
·
May 27

Zentalis reports 39% response rate in Phase 1b ovarian cancer trial combo

Reuters
·
May 22

Zentalis to join H.C. Wainwright BioConnect Conference fireside discussion

Reuters
·
May 14

Wedbush Keeps Their Hold Rating on Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
May 13

Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
May 13

Analysts Conflicted on These Healthcare Names: Omnicell (OMCL), Beam Therapeutics (BEAM) and Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
May 13

BRIEF-Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results And Clinical Progress

Reuters
·
May 13

Zentalis Pharmaceuticals Q1 EPS USD -0.5

THOMSON REUTERS
·
May 13

Zentalis Pharma Q1 EPS $(0.50) Misses $(0.47) Estimate

Benzinga Earnings
·
May 13

Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Zentalis Q1 net loss narrows to $35.35 million; operating loss improves to $37.86 million

Reuters
·
May 13

Zentalis initiates ASPENOVA Phase 3 trial of azenosertib in Cyclin E1-positive PROC

Reuters
·
May 13